-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Th6fwvJbc1HLtD8oBYe2Z/KG5n/LzmBylvTVTsLrVjvniiWA/AWEg5zp0AMH3o8s
 jLUpFqgXfjlpglMD/MdRrg==

<SEC-DOCUMENT>0001032210-02-001693.txt : 20021218
<SEC-HEADER>0001032210-02-001693.hdr.sgml : 20021218
<ACCEPTANCE-DATETIME>20021218122000
ACCESSION NUMBER:		0001032210-02-001693
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20021217
ITEM INFORMATION:		Other events
ITEM INFORMATION:		Financial statements and exhibits
FILED AS OF DATE:		20021218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TARGETED GENETICS CORP /WA/
		CENTRAL INDEX KEY:			0000921114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				911549568
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23930
		FILM NUMBER:		02861366

	BUSINESS ADDRESS:	
		STREET 1:		1100 OLIVE WAY
		STREET 2:		STE 100
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
		BUSINESS PHONE:		2066237612

	MAIL ADDRESS:	
		STREET 1:		1100 OLIVE WAY
		STREET 2:		STE 100
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K DATED DECEMBER 17, 2002
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K dated December 17, 2002</TITLE>
</HEAD>
  <BODY BGCOLOR="WHITE">

 <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="5" COLOR="#000000"><B>UNITED STATES </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman"
SIZE="5" COLOR="#000000"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="3" COLOR="#000000"><B>Washington, D.C. 20549 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <HR
SIZE="1" NOSHADE WIDTH="17%" COLOR="#000000"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="5" COLOR="#000000"><B>FORM 8-K </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV
ALIGN="center"><FONT FACE="Times New Roman" SIZE="5" COLOR="#000000"><B>CURRENT REPORT </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Pursuant to Section 13 or
15(d) of the Securities Exchange Act of 1934 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Date of Report (Date of earliest event
reported)&nbsp;&nbsp;<U>December 17, 2002&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <HR SIZE="1" NOSHADE WIDTH="17%"
COLOR="#000000"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="6" COLOR="#000000"><B>Targeted Genetics Corporation </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#000000"><B>(Exact name of registrant as specified in charter) </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <HR SIZE="1" NOSHADE WIDTH="17%" COLOR="#000000"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Washington</B></FONT></DIV> </TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>0-23930</B></FONT></DIV> </TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>91-1549568</B></FONT></DIV> </TD> </TR>
<TR>
<TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(State or other jurisdiction</B></FONT></DIV> </TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(Commission</B></FONT></DIV> </TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(IRS Employer</B></FONT></DIV> </TD> </TR>
<TR>
<TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>of incorporation)</B></FONT></DIV> </TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>File Number)</B></FONT></DIV> </TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>Identification No.)</B></FONT></DIV> </TD> </TR>
 </TABLE> </DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD VALIGN="top" ALIGN="center" WIDTH="48%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>1100 Olive Way, Suite 100, Seattle, Washington</B></FONT></DIV> </TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" WIDTH="48%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>98101</B></FONT></DIV> </TD> </TR>
<TR>
<TD VALIGN="top" ALIGN="center" WIDTH="48%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(Address of principal executive offices)</B></FONT></DIV> </TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" WIDTH="48%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>(Zip Code)</B></FONT></DIV> </TD> </TR>
 </TABLE> </DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Registrant&#146;s telephone
number, including area code&nbsp;&nbsp;<U>(206) 623-7612&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></FONT></DIV> <DIV><FONT
SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Not Applicable </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"
COLOR="#000000"><B>(Former name or former address, if changed since last report) </B></FONT></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Item 5. Other Events. </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV
STYLE="text-indent:4%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">On December 17, 2002, Targeted Genetics Corporation announced that it is initiating a strategic adjustment to its business strategy in order to best leverage its most
promising product development opportunities and to extend its operating capital. The text of the press release is set forth in Exhibit 99.1 attached to this release and incorporated herein by this reference. </FONT></DIV> <DIV><FONT
SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Item 7. Exhibits. </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000">(a) Financial statements of business acquired. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Not applicable. </FONT></DIV>
<DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:4%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">(b) Pro forma financial information. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV
STYLE="margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Not applicable. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:4%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">(c)
Exhibits. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0">

<TR>
<TD VALIGN="bottom" ALIGN="center"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>Exhibit No.</B></FONT></DIV> <HR SIZE="1" NOSHADE WIDTH="22" COLOR="#000000"></TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" WIDTH="86%"> <DIV><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>Description</B></FONT></DIV> <HR SIZE="1" NOSHADE WIDTH="73" ALIGN="left" COLOR="#000000"></TD> </TR>
<TR>
<TD HEIGHT="5"> </TD> </TR>
<TR>
<TD VALIGN="top" ALIGN="right" WIDTH="6%"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">99.1</FONT></DIV> </TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" WIDTH="86%"> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Press Release dated December 17, 2002</FONT></DIV> </TD> </TR>
 </TABLE> </DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"
COLOR="#000000"><B>SIGNATURES </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:4%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD COLSPAN="3"> <FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD> <FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" WIDTH="44%"> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">T<SMALL>ARGETED</SMALL> G<SMALL>ENETICS</SMALL> C<SMALL>ORPORATION</SMALL></FONT></DIV> <DIV><FONT
SIZE="1">&nbsp;</FONT></DIV> </TD> </TR>
<TR>
<TD HEIGHT="16"> </TD> </TR>
<TR>
<TD VALIGN="top" COLSPAN="3" WIDTH="44%"> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Date: December 17, 2002</FONT></DIV> </TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD> <FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" WIDTH="2%"> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">By:</FONT></DIV> </TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" WIDTH="44%"> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">/s/&nbsp;&nbsp;&nbsp;&nbsp;T<SMALL>ODD</SMALL> E. S<SMALL>IMPSON&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></DIV> <HR SIZE="1" NOSHADE
COLOR="#000000" ALIGN="left"></TD> </TR>
<TR>
<TD> <FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD> <FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD> <FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD> <FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" WIDTH="44%"> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Vice President, Finance and Administration and</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Chief Financial Officer, Secretary and
Treasurer</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">(Principal Financial and Accounting Officer)</FONT></DIV> </TD> </TR>
 </TABLE> </DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B><U>EXHIBIT INDEX</U> </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV
ALIGN="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD VALIGN="bottom" ALIGN="center"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>Exhibit No.</B></FONT></DIV> <HR SIZE="1" NOSHADE WIDTH="22" COLOR="#000000"></TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" WIDTH="93%"> <DIV><FONT FACE="Times New Roman" SIZE="1" COLOR="#000000"><B>Description</B></FONT></DIV> <HR SIZE="1" NOSHADE WIDTH="73" ALIGN="left" COLOR="#000000"></TD> </TR>
<TR>
<TD HEIGHT="5"> </TD> </TR>
<TR>
<TD VALIGN="top" ALIGN="right" WIDTH="6%"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">99.1</FONT></DIV> </TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" WIDTH="93%"> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Press Release dated December 17, 2002</FONT></DIV> </TD> </TR>
 </TABLE> </DIV>
 </BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE DATED DECEMBER 17, 2002
<TEXT>
<HTML><HEAD>
<TITLE>Press Release dated December 17, 2002</TITLE>
</HEAD>
  <BODY BGCOLOR="WHITE">

 <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B><U>Exhibit 99.1</U> </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>

<IMG SRC="g22226g64q70.jpg" ALT="LOGO"> </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD VALIGN="top" WIDTH="48%"> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Investor Contact:</B></FONT></DIV> </TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" WIDTH="48%"> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Media Contact:</B></FONT></DIV> </TD> </TR>
<TR>
<TD HEIGHT="16"> </TD> </TR>
<TR>
<TD VALIGN="top" WIDTH="48%"> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Targeted Genetics Corporation</FONT></DIV> </TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" WIDTH="48%"> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Targeted Genetics Corporation</FONT></DIV> </TD> </TR>
<TR>
<TD VALIGN="top" WIDTH="48%"> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Stephanie Seiler, Ph.D.</FONT></DIV> </TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" WIDTH="48%"> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Courtney Self</FONT></DIV> </TD> </TR>
<TR>
<TD VALIGN="top" WIDTH="48%"> <DIV STYLE="margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>(206) 521-7823</B></FONT></DIV> </TD>
<TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" WIDTH="48%"> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>(206) 521-7392</B></FONT></DIV> </TD> </TR>
 </TABLE> </DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>TARGETED GENETICS ADJUSTS
BUSINESS STRATEGY TO PURSUE NEAR TERM OPPORTUNITIES </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">- Reduction in expenses and focus on key strategic programs to
extend cash horizon - </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><B>Seattle, WA</B> &#150; December 17, 2002 &#150; Targeted Genetics Corporation (Nasdaq: TGEN) today announced
that it is initiating a strategic adjustment to its business strategy in order to best leverage its most promising product development opportunities and to extend its operating capital. The Company will focus on filing INDs for its product
development programs in rheumatoid arthritis and AIDS prophylaxis in 2003 and on advancing its clinical development program in cystic fibrosis. In concert with the narrowing of focus around the Company&#146;s key strategic assets and programs,
additional cost reduction measures are being implemented with the goal of extending the Company&#146;s operating capital to the end of 2003. Adjustments to the Company&#146;s operating plan will include reductions in expenses and continued pursuit
of partnerships or other strategic transactions that would provide value to the Company and its shareholders. Toward this end, the Company is undertaking the following actions: </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">-</FONT></DIV></TD>
<TD WIDTH="1%" VALIGN="top"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV></TD>
<TD ALIGN="left" VALIGN="top"><DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Reducing and consolidating fixed operating costs; </FONT></DIV> </TD></TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">-</FONT></DIV></TD>
<TD WIDTH="1%" VALIGN="top"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV></TD>
<TD ALIGN="left" VALIGN="top"><DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Identifying and pursuing development partners for the Company&#146;s hemophilia, cystic fibrosis and oncology product development programs; </FONT></DIV>
</TD></TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">-</FONT></DIV></TD>
<TD WIDTH="1%" VALIGN="top"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV></TD>
<TD ALIGN="left" VALIGN="top"><DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Exploring opportunities to derive revenue by leveraging the Company&#146;s manufacturing capacity; </FONT></DIV> </TD></TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">-</FONT></DIV></TD>
<TD WIDTH="1%" VALIGN="top"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV></TD>
<TD ALIGN="left" VALIGN="top"><DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Pursuing capital raising options available to the Company; </FONT></DIV> </TD></TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">-</FONT></DIV></TD>
<TD WIDTH="1%" VALIGN="top"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV></TD>
<TD ALIGN="left" VALIGN="top"><DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Consolidating the Company&#146;s operations in Seattle. </FONT></DIV> </TD></TR></TABLE> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT
FACE="Times New Roman" SIZE="2" COLOR="#000000">Additionally, the Company has notified approximately 70 employees that, subject to the outcome of these activities, their positions will be eliminated in 60 days. The 60-day notice is being provided in
keeping with the Worker Adjustment and Retraining Notification (WARN) Act. </FONT></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">&#147;2002 has been a challenging year for many in the biotechnology industry, and our circumstances are
not unique. We are adjusting our strategy so as to best weather this period of economic uncertainty,&#148; said H. Stewart Parker, President and Chief Executive Officer of Targeted Genetics. &#147;While we have made significant progress in a number
of our programs over the past 18 months, we cannot pursue all of our opportunities with our current financial resources. Therefore, we are concentrating our resources on our product development programs in AIDS prophylaxis, arthritis and cystic
fibrosis while we pursue our options to secure additional funding. We believe that the best way to realize the potential of our programs and our technologies is to extend our operating horizon so as to provide additional time to secure the financial
resources we need to fund these promising opportunities. The reduction in expenses and consolidation of our operations that we are undertaking now are intended to provide the operating horizon and reduced burn rate to better help us to accomplish
these objectives.&#148; </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000">Targeted Genetics develops gene therapy products for treating acquired and inherited diseases. The Company has a
lead clinical product development program targeting cystic fibrosis and a promising pipeline of product candidates focused on hemophilia, arthritis, cancer and AIDS prophylaxis. The Company has a broad platform of gene delivery technologies and,
through its majority-owned subsidiary, CellExSys, Inc., a promising body of technology for cellular therapy. For more information about Targeted Genetics Corporation and CellExSys, Inc., please visit the Company&#146;s web site at
http://www.targetedgenetics.com. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><I>NOTE: This release contains forward-looking statements regarding our proposed restructuring, the
research and development of our product candidates and the availability of financial resources, which are based on the opinions and estimates of our management at the time the statements are made and are subject to risks and uncertainties that could
cause actual results to differ materially from those expected or implied by the forward-looking statements. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of these forward-looking statements. Actual
results could differ materially from expectations for a number of reasons, including delayed progress and unfavorable results in our research and clinical trials, failure to successfully complete the restructuring and the failure to find additional
collaborative partners or funding, as well as the other risk factors described in the section entitled &#147;Factors Affecting Our Operating results, Our Business and Our Stock Price&#148; included in our Quarterly Report on Form 10-Q for the
quarter ended September 30, 2002 filed with the Securities and Exchange Commission. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no obligation to update any
forward-looking statement to reflect new information, circumstances or events after the date of this release or to reflect the occurrence of unanticipated events. </I></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2" COLOR="#000000">### </FONT></DIV>
 </BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g22226g64q70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g22226g64q70.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[1+D4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````D````'@````&`&<`-@`T
M`'$`-P`P`````0`````````````````````````!``````````````!X````
MD``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````$$@````!````70```'``
M``$8``!Z@```$"P`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!P`%T#`2(``A$!`Q$!_]T`!``&_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#T>G#Q[V.M>ZUSG/LD^K8.'O'T66[?:H9>'1CX[K:J,G*>TB**;W;W
M$D,]IR,BBGV[M[M]K%;Q/YGL??9QQ]-_DU1SL_$Z?1]HR[/2JD-W03J?HMA@
M<DIQ_JYU#I_UAP_M^+BYN/C/DU69%I`L]UE-OIMIR\AS?2LJ>U_J^E_P:)C9
MOU?R^C6=:HOMLZ=2RU[[A;?HR@O]9VS?ZGM]-_\`76'TS-^K_2OJL_ZM4=8(
MN;7=4S,]"S<TY+K+:[?19^<S[1^C_2_I-F]#IN^K&+TSK'3*>L.&'U2GTZA;
M5;8Z@G'9T]]GK/\`TF2STV8^VOV>EZ>Q)3T'3LOH'4VWFBV]CL,-^TUWOR:'
MUM</5KLMJR74O;797[V7?0>I=)R>C]68Y^%]K+&;+&/M^U5->QP_0W4/R/3;
MD4V-9_@US71<OZD=*P<[I8ZBR["ZH&AU3:KFO`=0S$R&^LXW/V7>GZU-?Z/[
M-ZOI5_X-$^K_`%?ZM]'NR<JWKIS!>RJEC/2L8`VEOIUV/KFYEF3Z'I,NMQZ\
M:NWT?Z/ZJ2G>Z;F=&ZABV9F&S.=176+FO>W,9ZC7`V,^R^ML^U[FU_\`:?U/
M_!$_2\[H?4V7V89R]N(37<;1EU;7,)%E7ZSZ?J75>G^E8S?97_A%@?53JOU>
M^KF$<(]6Q[\9@;'HX5N.XO\`H.R,A^_(]>Y];:FN]E?\VK72NM_5KIN/GTGJ
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M'^N]9/UQ87]':-N_]/3(\MVJU\0`4P#/OL_ZMZR?K>&'IE0>X-;]IIDF3^=_
M)24[<#73GE"RLG$Q*'Y.7;7116/?;:X,8T$[?<]\-:C*MU#I^%U/"MP,^IM^
M+>-ME3I@@'<WZ,.:YKF[V.:DI\XRNL?7*[(LMI^N'0,:I[B64,NI<U@_-8U]
MV)9:_P#MO0OVG]=__GWZ%_V[C_\`O$HY/U5RJ,BREGU&HR65NVMOKSGACQ^^
MP66M?[OY:'_S;RI_\0%<?^'S_P"E4E/4?5CZR.QZ;:OK-U_HV8X$&G(Q\BMK
MS^]7=7LQZO;_`(-U:ZZBS%R*67X[F74V-#J[:R'-<T_1<Q[/:YJ\L'U=LCW?
MXO6D^742/^_%=)]4;NL=/R:^EL^JK^D=-N<]]MWVSUVUNV_2;59/\X]C&;*W
M,_TJ2GLMC/W1]R`_:,ZF!J:[=1X33_)_[^K*KV3]MIX@UV>$\T\)*;"X:M[?
MVED-DZ=7H_,$1ORG<^E_H_\`A/\`,J_G.Y7"UMO_`&AD-V:_M>@S/(W97>/S
M7>[^NDI__]'T_$_F?#WOX_KO\FK+^MNX],K#6AQ.30`#K^>.)6GAF:._T[.?
MZ[UE_6UH=TVII!=.50($#EX]KMT?3^@DIVTDDDE+.:U[2UPEKA!!X(*XVW_%
M=TA]CG5]3ZI0QQ)937DC8P?FUU^K599L9^;ZECUV:K=1S1@85N6:;LGTFR*,
M=CK;7GAK*JJ_WG?V&?X3]&DI\?ZF[ZG]*SK\#.ROK-5D8SBRP&RB-/HO8?SJ
M[&^^M_Y[%Z)]4OJK@=*:WJ=-W4+;LNAL5=2LW64M?MM?4ZBMK&5W:5^MO]39
MZ?\`QBRQ_C`^L>D_4_J`D=MY_P#=9:_U<^M/4NKY=F-G=#R^DAK-]=U[7&MY
M!VOK]1U536/]S75_Z3]+_HTE/1(#Q^N4G72NSX<U>?\`WU'071]JKUUV60/G
M4DI,N"J;_E'),63^U\=W?C?EB/I+O5PE3V_M#)'J.W#JF/V]VK\QO&WZ.T?O
M)*?_TO3L(`4:<>I9_P"?'K,^MA`Z9620T#)IDN)`^G_)W.6GA"*(B/?9QYV/
M69];03TMD-WD9-'CI[V_N_YJ2G:226#]:\GK>+11;TS.Z?TVG<1DW]1):"2!
MZ-=)_F_])OW_`,C^6DIN=1^L'2,"UV+DYC*,G;N#2"[;NG8Y[6?!<C>SIF3D
M/O?]<NHM=:=:ZG"MHT=[*Z:Z-M7M_D*%?5OK5;:RNGZP_5NRZUY:QC7RY[G^
MUC6AOO<^UP8K_P"SO\9HT^T=&<T<?HK._EZ:2G-9C])+@?\`GIU0MC0BUVI]
MT^WT-NQO^OYBV/J_T46Y#,[%^LG4\^G'>"ZNU\U/D3Z3_5I_2-]-S-^SZ'\B
MQ;/0\7K;,>QW7[<:_)L=]#%K+:VM$[??;^DM>[Z7\A:C6M:-K0&@<`:!)2Z`
M\G[;4.WIV$_YU*.@/_IE6A_F[->WTJ>4E)UPM0M_:.2[8[_E3'(;)F-^9^=_
M.?1_-_?_`.VUW2X6IC/VEDM]-VS]J8_MAW[^8W?_`#G^D]F__P!5I*?_T_3<
M(`40WC?9^-C_`.59_P!5_F?06;];0T]*;N!(&10=(GZ;?%:>&(IYGWV:F?WW
M_O++^MQ`Z2"7!OZQ3J>/IM24[:I]7Q>FY73<BGJS6/Z>6%V2+3#`QGZ7>]VF
MST]GJ;U<7,?7:[ZSMJHQ^C=.P>I8E^YN8S/+2V06.H9Z5UV+6[=[_P#3?];_
M`,(E.+TWJ_\`B?Z9E,SL!^/3D,!V6>G>XMGNP6L?L?\`R_IKJ.D_6_ZM=9R3
MB],SZ\C(#=WI0YCB!SL;:VO?M_D+@?L7UOU_[$?JZ8,?S>/V_P#0Q$HJ^N^-
M>R_'^J?0*;ZCN996RAKVN!Y8]F:'-<DI]327*_5KK/UTOS74?63IF/C8[VS5
MDXMU9#'"?;?4<K(L>VW\Q]/\V_\`XSU*>H:]KV[F$.:>"#(T24R0'D?;:FSJ
M:K3'P=0CH#Y^VU>'I62?/=3Y_P#?4E)UPM6S]IY/O=/[4QW1I`._,=/T?^^K
MNEP=1_7\DP-G[5Q^[=L^IF,_J?SGM_XS_A$E/__4]/Q1%,;0WWOT'&KW>`;]
M)9?UM!/20`W=^GITUCZ;?W&O<M/#CT-/W[/^K?YN67];RT=(!<-!?3.L?GCC
MWU?]4DIVU0ZUT3IO7>GOZ?U*KUL=Y#N8<US3+;*WCW5O_P#5?T$?[?@'09-7
M;\]O?Z/?\Z4OVA@03]IJ@1)WM[_1[I*?+^L?5+ZM=+S[,0?5CJ^:QL%F3B.?
M;4]I_E,^@_\`?K>J#ND?5=OTOJAUX1XML'^O"]@&=A'C(J/;1[>VOBF.=@.;
M'VFJ'2)%@'QVN:Y)3X]^S/JE_P#.GUS[GKI/J;U3#Z5EMZ=TSH'6<:C.L8'_
M`&AKG4UGZ+LG])_->W^?>W_!U_\`!L1KOJ=UKU'NH^O&371)-;'DV.:S\QME
MWVROU'-;_A/39O6Y]5^FW]&9D#J/7W]9LO+"QU[@T5M;N$5L==?_`#CG^]V_
M_1I*>C0'D?;J1K/I6QS'TJ.?S5+[5C:?I6:\>X?WH7JUV9U7IV-=%5DM:0>7
M4ZI*;2X2IUG[2R?:[=^UL>#-D_SF8-VV?W/9]/\`\"7=K@ZJO\HY0C_O6QSQ
M_P`/F#=$?2_\#_PW\U^D24__U?3\7^9_MO\`^K<JOU@ZLSHO1LOJKZS<,2LO
M%3>7.^BQN[W;&;W?I+/\&Q4W]=LP;K,1W3,ZT5O<?6JJ-K'-<76[V6,'N^E]
M#^PAW?61EU3Z<CHN?;58W9=6[&<]KFNACV.8X;;:]KK-Z2E_J[U+,S<O/P>H
MV8EU^#Z(>S&HR*"Q[Q:VUKVYVYMU.ZK]4R<>S]/7_HU#ZI==S.OT6Y.3B4X]
M+3#"PVDEX<]C_=?C48]C?9]/%R,G_A%5Z3F=,Z.Q[.G="ZE5ZNP6$TVV.+6-
M].FOU<FQ[_1H9[*J=_H4_P"#_P`(H=(NZ3T9Q_9W1.KU-<TMVN;?:P-+O4=M
MJRLBUE?Z1WJ?HV)*3?5WZWT=<ZC^SCBMIN8S*LN:0?HT748^+;27-_2TY++[
M/TG^FQ[4?H_7<WJ?6L_!;B4,Q>G7OHMMW6^H8'Z)S&_9OL;M_P"?5]M]6O\`
MT:J8%_1NFW,OP_J_U*JZFJRFNST'N=Z5UOVVVMSGVOW[LK]*SU/YK?[/3_2*
M.+;TK#S[.I8_1>K5Y-UEEUNE[F%]H#;K?LSLAV-NL:W\VK_!U_\`!I*=3'SN
MJV?6"_IEN%B-Q:*VWG(;<XV>E<[(JQOT#L9C?7<_#_3L];TZO]-:BMZS0+.L
M_:*@RCHQ;O>/<7M^SUYSW^GM_,;=Z>U4F]=QVYEF<WH_4ADVL9CV/]%T;*W6
MOJ!;ZGI?HWWW>]OO_2*-76,2BW+O9T;J`MS7-?E;JBX.+6#';+76.K;^AI]/
MV)*;_1,WJ&?C?;,S`IQZ[:J[\0TW"YSVV-=9Z=FZK';7=6W9]&RRE_J?SJK_
M`%7^L-W6?M#<G&KP;Z!6YV,'6^LS?N/IY-&7BX3V>EMV>M3Z^-<_U/2M_1*E
MTS*Z9TLW?8.B]1I]=K6OEKW'96+#155ZUS_0JI:;?2HI].JG?[$NF9/3.D@?
M8>C]0;NK;4'6"RYS:J=WIX['Y=UKZ:*=SME%?Z+WI*>K7!U.'[1R1&O[6Q__
M`#YF63_K_P"W2Z%WUFV@_P"3<T[>0*NP#W;AK]']&L"MG4/M&1EG'NV'J-%X
M9Z9WFH#)W>S^JYJ2G__9.$))300A``````!5`````0$````/`$$`9`!O`&(`
M90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T
M`&\`<P!H`&\`<``@`#8`+@`P`````0`X0DE-!`8```````<`"``!``$!`/_N
M``Y!9&]B90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!
M`0$!`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`__``!$(`)``>`,!$0`"$0$#$0'_W0`$``__Q`!X```!
M!`,!`0$````````````)``<("@0%!@,""P$!`````````````````````!``
M`00"`00"`0,"`P8'`0```P$"!`4&!P@`$A,)$10*(2(5(QA!%A<Q,B28V%EC
M-)57E]<9*1$!`````````````````````/_:``P#`0`"$0,1`#\`NR8YJ7',
MYCWV19!E^W)\^5GFTH*+0;YWEA]3`A5VP,NH(E3!I,4S7$ZJ(.HA1D`WLBKX
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M1P8L_(LDY><@,7QV(DF7"9`05E/W)7U-3(FRA"&QX7A(=2.'\N0KVO#G<0Q+
MC-E]+=Y3@^\,RS'',4:]N2Y!CW-G>N4T..I!&+(#K?V</=]C6U;@0FM.59+V
M+]-51Z^!RHH8>'U'%7/9U?38%R`R+-K09C.A5N*<X=UY/92BPAELI+"1JG>4
MZ79MC1GN(494*UH$3N3QM1$#IKK"-`XW,EP,AVWG%#/B_2^["NN7^\:N5$^8
M)AQ//%G;C`6+]F):>3]6M\[G"*[N>,+VANK?6>GL0[4R/86QL>_F`N!&_P`Q
M\I]Z0/M,@!<`SJU;?;(U88#+%JF)'[2*]PWO<KVC<@;Z#I3`BP(+H.1;<EP7
M#C2X4MO(W?L])0'0),6.=+!^SSEGQSQ)[B?+B$84B#,OR40GL#91=-8A#?'(
M*XVL]T9O:-)6]]X3F.3Z[(WS(%-V)('+=XV(OR5'KY/DGSWJKE`=>:<E\MX]
M^P/`M`P9-EDFI-NT.!U4RKRG)LTS+)<<S7(;FWIZR[QVPR2WNI\&EE(X:S_A
M30_^%^%8%[GR1!__T+UVJ!C%B]HT4B5):NRMSD4DP@BE:0VX<Z*:.QP2%8D6
M(5[A`:JHY@&,:Y&N16H#E=`"_P!WNF<\VH_U*2M;ZHR[8[\#]WG`;9>SY&$8
M+<Y@_#-4XXNS866Y_GI:&KL5QW7M"LV"&QM;!0UL52@:8K>X:*$E?;G+W)#]
M?VXM2\8,"RS*MT<D28GQ5UY78#7V\(>*$Y&Y=5ZSS#8&193C^.9(S5N)X)@F
M1V]O+RB3$6)3EC#,]['JQW01X]&>(;GX\:?Y)\%MQ:8O-.UW$'DWG$#0L%+R
M^V/@4GC;OQ@.0>LL<PS>5UBN'MW!,UO-S^UH[*6R&(T#ZL:-(8(S5",`/^E#
MB-OO7?+CUG;6WQHT.J<%L->^R>\U=D>L^)-IJ;;Y-OU^U<XU],UW[`=GSZ)^
M1Y!AN3:6N9&6X!)MUI8\RR!!B`%(-!4L@)F^[+5^V*WF'E6YLJX:U_-+6^5<
M-,,U3Q0C;)XL;#YM:#U/O&#N#)+_`'EBN6Z3U*^-L'7>S-W8)*H(F-9U%DU@
MXYH?UWV#$"HQ@^OLSPO<N?\`XVE-A5_QU-K[=UCJ;U])D'&O4FEKW8D?6-OC
M7('C;?YE@^+:/=<YS>7&.ZYQNBGH^DL+&25:Z"^/..URF5`FSZA8''FVXIY?
MJW`]38W42(>07]9O6XK/6M:^M+`-TV68NM_XNQC\=<@I8T:U'6ZS6NQ^RF)*
MM!RW055Y&(5(XPCIZK>$.EM'^PCVTYUCG$'6^FXN.<B-44?&_,:;C]CNMXE/
MK6ZXX86+.J7260P\1I(\7`[;+VRG6L6B,E<>Q[GG8XR]W0#HWMB6N\.]_/+C
M<G)'14C/]/'_`+*28G#O_4UFW-LFQ[C'="38-H?4G).MQ*]@\;K3`,JGT4BR
ME1@3V6Y@B"1\1]:XB`1OW(4^EDY?^K'..3W'#(.2G&C!IG-LVT\4@\6,PY<8
MY7S[_36#U.O)&3:RQ37NR$<27F;H[:^1)@=@9(_,CV(%Y!A+/TTZXV?J_AK,
MHL^P+/-/X7:\C.3F6\9M&;1@SZG8FB>)64;IRVVX\ZFRRCM+2YL<9F8M@)P?
M6J#R2%IJ\\>"Y!K'4;`*WT%>3F#/RC_]>^,,.NL_HU4.PTM82P.MYR0I,23F
M2T4H<JMCF:1LR:.\*$*`[7>5`+(1T$DUKP__T;V6K3%/C-F\P`QWMV-N$*#!
M&'$8X4?;>;QP'<(3&->:2$32$*J=QB/<1RJYRJH.-T`)@["Y[;^Y8<K=.:?W
M30ZXQ_4\[(H^.OR2B$V**'83"5]#$0@*&^GLE+*@C>V6K'(D%[RA:A7.:\'.
MB\>?;T.%%21S-TP^2A+A\V(+$S^!R2%&"N''M9.MI%A]?QQQG>Q1M)'<I0"*
MY2K*:&=)X]>VM[T8#F9IY&"#+;&DNPTXU";YKV0'FKV8&3^0:U@3O)YI3OWO
M1/A[57X"+FTYGL<T6^OQS='M6X#Z;R#(@R+&HA[7R&BP:YFXX*W(UDJFCY;1
MT1K8,=PT">4&.-Q#M5B%$+N`X&=C[KY7#B5:2/>+ZR9<N$-BRT=NO6X/N2`W
M46P:5LN*,`6_:B,>PC30Y(6=JB0;HY?&$,Z1OGE22W9.C>[3UAP(PG#008>\
M=9D"HALED$DFNNZN^BRG`FSE([Y<UT@81"*Y1M^%"4-/HCV^YIBU?DN'\\N/
M]]19..NR7%<IQTCKW'K7&K`2S:B526U9IY\"WI["L)',V2,AV3'.<4;QQWMC
M]!T#N,?N%9$\$;F7JM"MD+,CEDS+60H"H685(LE[M'>>RKR/DM5['/$J#&P3
M%9VN>0,IG&[W'LG19C>:VI5%&<YY()*R(:--19`Y`XQT=H!%&$$4;H2O;_6*
M,GV%<T[/WAN,?X[>WBLC_4M.8^J;GRUKQR+"7!"Z;_(_Q\B,-X!1-$UT<`4E
ME;(5[.QW>Q$[.Q.U0F7Q`B\B:*LV/AW)G9-+LK8&,9-2,BV6-BJQT<+'[3%:
MN?!!%?&Q7$[B3*D2'F?().CM52_M"U!M\A@F-T%?#E_C5?;>VGCA*D3ZN']6
MTT/9$'.SIU5)DRZS8<296B@TB0Q.DR#R8(QMB^0C3_*M4C?M.`0/_]*]AJI#
MMQBT22V.TG^I&Y%:D9C&#\#MO9RZ*YR#!&:LAT56*9>U7.*KE5SU57N!R.@#
M[PGA/!S]Y]R6609L65DQ2(@B1WF;+_S`T4B/)`.0:5`#6-`T`&E:,1R)(*%.
M]TE5`P70-ON/;&#Z%U'M'>.S;0E'KC3>N\TVGGUR&%*LCU6&8!CEEE>36$>M
M@B/.L9$2EJC/''`QYCO:C&-<]R(H?G1\P>0WXMG.CD5LKE#R&WY[.\EVCM"X
M98VQ(-/5P:"AK844-;08EB52?7\U]-B>+4T4,*!&4QB-")'%*4SB%>$:/\G?
MA^_^Z_L__P#3J3_ZUZ!?Y._#]_\`=?V?_P#IU)_]:]`<[U[^^[T-^MG21^/&
MD-_<],VU,#()>18KC>[=>LSEVOCV;46YJ\'L:RBQ>PJ,;MYC4EDK2$D0PS7%
M/'&`DF4XX6I.#O/OBO[%M,1]Z\4-F0=@X<RR-19%7&C'I<SP;)([$*7',YQ&
MP0=OC=LZ,]IP(9BAF1GL/'(8+VD4)D]`N@:/")L\^S-UPS_82O@W&#I`8^7`
M-&<63@U4::8$6)$CRH9'N\;"?:(<Q/&US7M%XQL!W.@`;RJM94?VS\=AQ*<T
MMLAVF::3+2XQ^N6.U,PG63C#;8P;*0T*1)9'JQ/KFL$C%C1U:96%:'__T[VF
MKX@(>-688SAN&_8FWI;E$%X&^>?MG-9TIJL(0CG$;*D/1[_E&D>BN1&HJ-0'
M$Z`1O!^NKX_-OGY-#8ULJP-L*='D@BPK(<P(6Y#)L!CESY@(T66&*ZQ[&-CH
M48SN.WRN>U[!@7+H-;<TU1D51:X_D%56WM!>ULZFNZ2Y@Q;.HN:BSBEA655:
MULT1X5C6V,([PG`9CQ&$]S'M5JJG04L/9C2[*X1\C;#7NBOQ;>"',G1-Y#;>
MZTW%I#@Y5;)F3*OM:EA0[&H=:Z*RIVO,PHYTED?Q2_B-:`%]N&]S2%!"`?#.
M7?(U/CR?A<:3?_4&J]GK(SH?R).[RL3NXH%^"/\`E.UWZHWX7Y:[Y_0,B-R]
MY!L^/N?A8Z;/_417?6]:6;1/D7[?EB>7B+-[2+\+^[]43Y3]OZ?J&\#S%V\T
M0$D?A-ZW*=O_`)D@?7GDX!%_:]/Z`7\'I+X_[U:O[B%_1%3_`!14!^-!^WCF
M-Q>R67;:)_$KS#CL?,)%7CV9V6@^,&TM29+E-5`GMDI1RYF'<-L??=R(3Y#R
M18TIQ1CD/1W:GRJJ%[JFL'V]/56I($ZJ?9UL&P?668%C65<^;%%)=`L(SOUC
MSH:D\96+^K"-5/\`#H-ET#4X6^T38NY02Q-96_S6&2JA[(U8#S-/@U/&G/(6
M.O\`+3#-E0>U224036(U@?E6%^`=;H`!<H)=Y2^WCCU8#K7%KYLK4T`<IJT#
MG$!:SY^/F<K9D99!'0_Y&20;2.(4`62GQ6M.49@A_]2]IJ\\61C5F2(X;A-V
M)MX#U%(D26_:C;9S6--:I)0Q$:1LP1$>-$48GHK!JX;6N4'$Z`1O"1U*3G5[
M!_XV.X,D695Z2#%DD>LA2W=RV:P$4B_(6@N8LE[R=Q$(D@;6H)K/@@%RZ!=`
MN@#O[5^)WL_WO487EWK`Y[AXK[*I3,ILRUSLRJQR9I;-L=(^3(3(X]\+36UL
MZQ7.JHQ$$K!19=;915:US(A0J4X`^L/7Y^7E4PI%E:^X'AI65\,:FES["\M(
M<**)%1%+(E2>!(P`&BJB=SG(GZ]!Q?\`:)^5=_WO^`'_`,BQ_P#H7Z";_`SA
M#^1E7\C]2;#YG>V71&S>*6/7A,CSG$=!NKLMR79;*)3NK\)%+O.)^M:BNQNY
MO8S8]O,!:_;##880!^9Z$$%I[H%T#4X;#*+9.XYI.WQR[+"1`1D.$+]D3#8/
M<XDV,1TF892G<BMD-:03$;V_(W,7H'6Z``W*8M^3V[<=8L2\=%JFMU`\L-K,
M?>JN=D-U*.$PYE=,GOA%AUIPH\#DELDSQN^!A8D@0?_5O::O,0^-6;R)(:YN
MQ-O!1))&D)XXVV<UCB5KF@CHD=PA(H6]JJT2M:KGJG>X'$Z`2O"&2:5S;]A2
M&AP8_P!38T4`Y#OV6<E'RY3?$$?V!"+4QXT8)E,*,JNE3"#+(>\;1B`M70+H
M%T"Z#B]C:ZP3;V`YCJW9^)T>=:ZV%C=OB&;8;DL`-G0Y-C-]"-76]-:P3M<.
M1#G0SO8Y/T5/GY:J.1%0*BF2?A4>NNUO;JRH.1O+W%:JQMITZKQR/>ZEMX6/
MU\J9*D1J2)/M=6FMYT6LC%$`1I1S27L%W%>1[U<@6JN,?'+5O$7C_J;C3I6F
M-0ZOTUAM9A>)0)4LUA/?#@H0TRTM9YU4LZZO;60>=-,O:A9<@CD:U%1J`^O0
M+H&SQ$`F9[MH[&PVE/<8FAO'':R<_P`6&5#1OER4(KCQ^UW:%JL;XU:3X<[N
M^&`YG05^^5#\2+[;^/(I+1@MP9!I8DATR&:2P\MLFZ2ND0W-N@L7YDRH$?X0
M('`.K#]QQM+%DA__UKTFG"$+B5NXA9!G)M3>HT?)"T!$&'=VPA"$UC2E1T<`
MF(P+_E%()K7JUJN[4!U.@%7PF0Z\QO8,6196$KNV96BBL?---K90!2;A'F#]
MBIAECR*1596J)#E8)([FL^1HQ[@*IT"Z!=!RN:9UA&ML<L,QV)F.*X%B-2T;
M[7*<TR&HQ;'*QI2-$)UA>7DR#60VE*]&M4A6HYRHB?KT`+?:4&[YO8AA>`<7
M_>1H;U\X'5VT&VS')]5YOCDO;N;9`P=G(A5`]I8IR5U;9X_B(ZIPY*54%`EG
M%$1\HYX_C$$`FQ_5ARN)/&*+^8/GT@DD/V61V\B\\D'(4E5_)`+'B?WW%&^"
M6`=TQ&M:C?K(QR?*(TK0E/PNX5<D.,/)?6F[LM_*!K>4^#X)=)/RS0VYMP7N
M8X-L/$K2ELJB[HKB'DW,;+ZFNLG4LO[-7;OKIO\`'6(F34C$>-$<%P&/(CS(
MX)<0X9464$4B-)CE8>/(CG8TH3@,)SAF"8;D<US55KFJBHOQT'MT#?XL4I,P
MV<QX8XQ`O,=&$HG.4TCNPVB,1\IBB:UI&.)V-5'.^6-3Y^/C]0<#H`"\L+>]
MC>U_CG7PGQ9]?,R;1HY=;6WMS`FUX!V.1DD6]I!K[:OCG,Q"]KT(.0TT/Q">
MQ0D,C@__U[U6HTC)BMM]5SG"_P!3MV*Y7-KV+]E=S9ZLQJ)6/?&5K9?>B*Y?
ML.1$4Z(=2(@.=T`G^&!ZY>;O/6**PCRK`>:#,:-&I:P21(Y+4_:XV2B^;2U(
M20KQ+#*J"@DC$5J*IE7H"P=`N@C_`,A^3FGN+N*5N6;=R,E2"]M%IL<IJV$:
MVR+(K$<=\V6*IJH_PYT>NA#4LF29X8H/D;'D0I@#*`-^8VU_3CSW2@3EI5[?
MV1CV-6Q;;':*WO<WI<'III:R#6R3Q:"DS:#35[;NNAL(?R"8\K6J4G:CT<\(
M($X._C#5-66/_;?ETF%6NIZDIGV>VWSX?\;$'#$`D^9F@+9[KF#;--*[B/?8
MD.CW>24G[0QZOA%^,\MO9V$[C=D5LMDU[*B#_&;5BC@4<O'H=;\RAESB2EE9
M^1)!DM5:`K9!V._\Z+[#PDSQG],WX_W)NYM$U!PPS"UB0*-EM<7F26FRH6*1
M8EQ4#Q>!%+(L,T."NO)L6M=*CQ`C#-'+\\WL9(:<K`L_81AF,ZXPO$->855#
MHL-P/%Z##,2I`R)DL5/C.+U,2CH:H4JPD2Y\D=?501!:0Y2F>C/E[W.554.H
MZ!J<'8;_`#_NHI7!>UV58F&,X99#BCCBUOB1%CG$4;0#<R3(*1JB<YKFE3N^
M'(O0.MT`!N5<3(;#VR\<I+8[A5E1DNEA1I#16\8AH*NRJ19)]N/!F0#09,R>
MU#N-V#0\.+':4!)"I)#_T+TFG!M'B5NU@"1T7:F]2*,H"QW.<7=VPBO.@S29
M;W#E/>I6/1R,*QZ/:P;7(-H.IT`C^$Q(W]]'L%'%K9`>[.(OV9;W5)@B(&QD
M.2,I`1&609$^5*DRT:I4$X!!M<Q2B<5X%PZ`8GLIY&>PC0V-ZX%Z^N&M'ROS
M/)+B<_.)&6Y8'',9PG'H1JJ$(:Q6WV-3K&XM'6Q)8WLE>,4:L./Q%,<*-`+]
MGSN_(KO)<S_.'I6XW79XM3#BLM9=M=W@I+5EDE3*P#).=S)[XL.7#0S1HGB(
MXPB,<Y[7M:&K+SA]_K?%/N/1IQZ.D&+6$"R&`]G8%><UM+F0(RASZ22L=5_7
M'WO:R2-QI:."A?@C6AXT?/#WO1X\27.]$ND(5JZ/Y#BKZRVC.C-+&F"L8[98
M+ZP&OU2%`%_:]SY3'E='&<;5<@6(>(6.;?SG1&-95S!T%Q_U3MO,1AR&[U1K
M.E_G:G#(\H`S0:C)KN\9(%=9A&0CEF.C#;&C%51,(;M4BA+ZFH*+'(:U^/4M
M30P'&?(6#35T.KAK((UC2'6-!"`*F(T;4<[M[E1J?*_HG0;;H%T#7X4\3L[W
M&UDTD@C,HQ?RQ'FB$;`<[7>**Q@1@3[,<<AGP16G7N5ZN<U$8Y/D'0Z"O_RP
M;3Q/;)QQ-%M?IVT_)],#MU=E\['FK';-L`QZ=\2#"&EC_(G'"<&*4LH4][R1
MR`&U[)L,/__1O4:A68N*6WWC#.;_`%0W>C'B%("UL--TY^E<%6284`BDCU_B
M&]R#<-[VJX9#,5IG@Z'0"IX:Q;1>;O/R7+@A'7BS*F'`F#IW1&N-,-*^R,,]
MCRQ2N+%K8SY#6O4AC-\Q&"5R-Z`JW01PY>:5SCD3QLV]IO66ZL\XZ;)S;$Y$
M/7^[=;7%I299KK-($F-;XS?`DTTZLL)E.VXKPAM(+#A_D*LLB,KV>7N0*L;/
M1=^0`KVH3\@C:+6*YJ/<RXWD][6?*=SFL=F@T>Y$_P!B*YJ*O^*?[>@M/<3M
M"7O&C0V"Z@RO>NXN2N7X[!(7+MV[TRF9E.P,\R6P*LNWLSDDGD`H*$<EZBK*
MF.\@J^",8GEDG0THX2-Z!=`N@70+H&WQ%57-ML?->2*K<@QD;9KXT8+;0:8-
MCQ$,$HG+(ECC$(X*O*B*U[',;\M9^@.1T`#>6X[-OM6XYFAX_.D1B76@P2+>
M'$BHL5X\OR$A9,BR'.9*9!-6E.%\=RQ_*@'N<*6T8FB#_]*]5J.4*9BML41S
M2&LV=NR*I#SKJP>TL'<V>PC`:>^:V<,,8T=PQ@'_`,%%&QH8:K$&!>@<[H!(
M\,FP?[]>?1(RM\[LB@ME-1Y'=JCMC]JHA'([M>9Q7?/8U.]7,:KFL:Y0+=T'
M/Y9:7-'BN2W6.8S,S7(:C'[FTHL-K[*HIK#+;FOKI,NKQF#;Y!,KZ&JF7TT3
M(HI,Z0"&!Y4>8C!M<Y`INY)D_P":%:9%?65#KCBSC5'8W5I.IL<CVG%FPCT%
M3+G'D5U("?:YA.M)H:J&1@&FDG-((T:.(][U5RAIVW?YJ[555Q#BZ].U[>UT
MGB8B(KF.:UZ=F4,7N&J]R?K\?*)\HJ?**%B7UA[(]F67ZALL;]HG';"=3;PQ
M2=V5VQ]5Y]KO)]?;8H9IY!(LA^*XIEV17&"Y=1#1H)H7-)636(R1'*%[WQ`@
M37H%T"Z!=`UN$PY\?/-S2)+6LAS\JQ8];XZ[ZS2"#KG$HDDI9Z.>VSE+*CN8
MY5[7!$P;%;\=KG`Z70`!Y6DL1^V+CRT:!BQUR+2)!&6$)P9J%N)<28(TFOLV
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M&M#^YS5:YZHYKD:T,D?`#@8[PN7\MYJM5L9"(NO=FB>YY@S"*YJ$Y<*H&JH$
M54<CE"J(QZ]Q1]!]`]??!$PXJ)^7#'0I"#4CR8!LF,-XGN7]GCD<OF.A$[7(
MBN(]R,5%5S?\$`T/J*WCPF]8F19Y69C^2)I;F%I78@0V5EJC9^"V]!.Q[.A5
MT6/!S7"=B7F_]C3,;-(@0OK6D%81XDX+(["(*2`1N@M1<7^:_$SFI193DG%+
MD#K'?%/@]M"H\P/KW)(MQ(QFRLX;Y]4&[KOZ-E7!MHH2NB'*%H)3HYVB>]X#
M-&$H>@70-3@T!(N?;KEI]7YL\NQ60Y0U[XDCY!K3#87Q+F..1+1R)&3L(U@T
M&Q4%\*K%50=;H``\K:2QF>V?CV2((+VMMM%VKDGXF)1%BQ,CMEFNKK&5$05X
M:!&JRD)+81RU1R1OA4,T#>@__]2]YKA\LF/V+IH/K&3/-IL8/[`I/=$'L[+Q
MP#^000-;]J"P9?&K5<+O['.>YJO<'>=`)7AL=5Y[<^(_UZUJ.NJB4A079K"S
M1Z75E"(^?`<:4&`&6V(Q!,10*-(ZIXE[G$<!:N@;W;.J==[UUCG^F=MXI6YS
MK':.(WV"Y[B%O]EM?D.+9-72*JYK#FA'B3X;I$.2Y!R(Q@RHQ.TH2#*QCVA2
MO]LW`7\>CU#P]6Y/NKU"[]VAK':QK&EJ=GZEY,\@9>-46<5;33"X-DX<HY9X
M]:5-U84;/OP'J%T><$4EHGJ^(=K0"M_>U^)=_P!FOE__`,R6W/\`K3Z!?WM?
MB7?]FOE__P`R6W/^M/H%_>U^)=_V:^7_`/S);<_ZT^@E3P^]VWXZW`7;;-Y<
M1?6;S=TSLS^!M<7F757O_-\DJKK';H2#GTN38;F_+C)L)RJM\PQR0"LJZ4R)
M.`"6!!R0!*P/T0M(;2K]XZ7U#NNHH,DQ6JW!J_`-I5F+YE7.I\OQNOV!BE3E
MD*@RJH>KGU624\:W;'G1E55!*&]B_P"[T#H=`T^"K6.V!NUT(?;.;EF)AN"(
M&Q&TDINM<0-%12RWOAR",KY`D5T5&C:U6M>GE1[G`['05XN7DJ(GMSX^1GUE
M"5S[KCBU\\\#((UI',S.+(P2?8##G4=PXCU",!.QQ(ZHY"K#:,4IX?_5O::O
M4RXU9J<L@S_]1-O(U\E0*1`MVSFK8XFK':T?UP1T:P*+^]!-;WJK^Y>@<3H!
M2\/94H_.KG@W^4MID(5]5`^O-=CZQ`S`64ESDC,A$_EVMBQI#`#<]'#<(:(1
M6F9VJ!6N@70+H/$\>/)8@Y(`R&(Y'HPXF%8CT16HY&D:Y$<B.5/G_;\+T$+.
M;&K]YV'&[84CA-C/'T');'J4=SK"FW3K.KRG7V8R\>B.\>O+%!7>(KC9LD@!
M2#7VCYB1:V0HG'8L9"?`5'7\AORTF/<QWJ:X?*K'.:JLU7J$C%5JJBJT@^3S
MF/;\I^BM545/U1>@*7ZD\B]X&XN1.21O9QP?XG<>N.6-ZYM+&!;XUK;!8><Y
M1LN5;T\;%J7'78]M_8;P08=<VPF3Y$B$T+&A$)'H4XU0+.'0+H&KP997^>]U
M(>,,$=,PQCZ1FN)Y)@EUGA7E,1CU<Q/')[Q(K%:BH/X5J*BN>#J=!7RY:?=3
MVY<>E1\UPDL^/C@Q76%W&K7"-E>3CDRAF%\!!-"V.1'QA?,:8/L85?A\A.@_
M_]:]AJJ.L7&+02L&SNV1N21\"9&8U4F;>SF6CU2*\@E(1#]SU5?(YZJI$0BN
M1`<CH!S9%I[6O%S:&UN2N2\K<-T3_KE=+7W$_9\74>,8JDUZ2I6.TE/?9::D
MD2+*/,*0Q1OEE?/1J?TV/1Q'!)6DQC:UY55%Q4<D:^^H[2&MA$NZ;6^%3(MQ
M76D9CH,^GLXEC+JR1Q1W-/$,T<@3R.[B(<2H)`V2X)NQ13T_UZ"T\HPGQ'LU
M5C*!K`M(4A@Q@OM"/.XB*P;7G(7L&UWRCGN1[`^18%NT;E5^_1G8L,P$:75.
M+(YLH@GHR<CPV(4\D<[D<QBM4:L:C7(Y?ERA[$PC=9"@(F\X(6@"]J@CZIHD
M#,D(-W@+.61?23J%#]JE''?&<0?<UCQ.5"-#Z=@VY$<9PMZ_/?(F/`R1K'%B
MC#&,2*Z&!Z`EQ"&)#&(K5)W-\JE15:WL^'!Z%PS<Q`F&W=E>$I1E1AQ:LIE=
M'*0XWL>$9K\HW#!'8K&M(CU5SU<YSOVM:&4F&[60@'_ZSN5@VJI1.UYC/9(-
MY45B$<T[2LB^!51S&.:12=KD(C44;@]H>*[9CQWM/MJKGRU&-HS2-;0!1FD9
M,0[B/BP\CBE?Y8GR!40S43]'I\.1?D,P6-;+02H;9\,A_(94(+`JT(D$YKT`
MQ0OMSO4@WJU7N\B(]$5$:SY14#:8?B4_')F465ID1,AGY3:0[.25:F!4!BN@
M5,*DCA`&%W.+\P:X7>\KWN5Z*K>UJHQH=QT``>6?B-[8N/XNP*.';\<%(X=@
M1)8U;EV;S!%;$:!OU6SGQFC.X1VO.**P<ECPN`G0?__7O::O,`^-6;X[>P;=
MB;>"Y/`&-\GC[9S4$EWC`YS'=\D;W>15[R_/>]$>YR(#B=!4$]NN385IKVA9
M5N?F!K[CCE6N)'`K!<(X`9;SKU[LS..">-;H)O.QM.2N)Y_(PG$<_KL7W#DN
MKF+(A3UII5D>$&NC!4C52(<"6\*<VI,X]!<7.;#CIA_$#$+CAYR5L1\?ZRCR
M;%\-UOAD>-MH$4KX^QF`OIE7E5#&;?GM)Z*.V99NG-(8!V'(`]/Q>+KBK.UG
MV8GFW%3(.5=GQOTS:YW6:"VQRAS79J88.BQIV73>2.*[ONI^O,=VO#V3:A'9
M.Q`3*L4XYP1NR(T;5`7'MTR3DOK/F9[J-L:MFR,^XV;&W!ZZN*'(+$84V7WZ
M3NI>F>)VU=0;SK94.P,*!#/L.DN\1LA.C!$LZ_$UY'R2C\('\_)PLJ&N]>6M
MQ9%<:^IJVWYP\3J66;:N9YUK[7,JKGYK/;DT'.LRU9*A;4QS!3X@RQ6_FXP1
MM_#H6S#PE0PVJ@2E]0.&\-<B]>L'"^,]CJC*M=Y9(R?']]#T'N3D1M75#]S7
M6'8Y3;7JM?;&W_DMANJ/CY*DD+Z?GDPI(`E89!ADO*[H(+>H;U\<2=2<^?99
MF.OL9SJ-D/$_E31:ET/!N>06],VI==8!G'%'6&0Y/"?C.7[0R"#EDZ_R+8=\
MY;#(P6LJ.Y_9",!0N1H3GQ+)$-[Z=X8E#R%QX$+U1<=[Z=C`+EYH4#*YW*_D
M+!LK<]&V2^/"OIN+PZ09S*)ARPF0D>JC0/0"WY`YOQ`7VD<NY'L]WCR/U5LO
M5NS.(#?6MB6#;9Y!ZMJIFF<GQ;7X<DR/CCB^F[RF%M_*,TW?,OJS8Y5A7-C7
M5D;P!=%%'5P0F[[_`*LQZYT!Q\@9)RVTUQNKF\A8=C)U_P`ELPW-KCC5R<C5
M>`YE+)JO=FRM`W6+[$U_CM;(:&V@6)K,5$^YC1(DR/+D28`T"0_I'VRW<7KI
MT_D,;`,JP&IH\BVIA-"N1;<V1OBHSBDQ79635\'9&L]N[=#'V/F^H<O3N-C4
MBU9YP5;1QFO*(##$`LO0`&Y4U]LOMKXX3HG:^,6VU.!426QCPLAV$N18/8P\
M,H0-=!,YLE7H[S=T04<HSD>C0__0M);8Y2\L^.VR<KUKA'"3+MO85_/9)F&,
MYO@%'E):BXAYMEMQE5D^QD8[49)5P;J+,R`OVAE>.=)-$,9(W_%@Z#C">Q3F
M(%?T]=6[I;"*(`',PK:,5WF`RY%/E%&[!92B@R)L>)]=">(C8KB%5'D<$#PQ
MP>QSF0Y"A-ZV=ZM/&=`0DMF+;'2'+1E&(EG]`!,#;(5TJ\-_0\KF,``;AO<5
M_P`%Z#8@]C'+U\L2/]:N]%AOAN>5'5NQ8LD$D0F][E([5,D!O(J.(P#4_P#!
M0SE1I2!K_P#]%>8SSB(SUD[LD2%KW>*4^NSV&ZO5S(9+(!B2]8HIQD*/RM$!
M_<9D7L;WF<%CPVZ>Q+F`L@/_`/-'>7TRN&)'-'FOVU(X,,D@SQ%UD`4:+#>=
MZ_)7M<<2)V(DAI(K`QF^Q3F*>>"./UL;FBQU;'(5TH.P'2#L?W.DI&&FK`#&
MV,-B?O>Y4[C#:]HR?(^@\2>Q+EQ%+8D%ZW=P-87^6F-*D+.F&<VLBQU61:)&
MUI)$:1$A`0)&@(=Y3H..+]6JO0>!O8_RV&"OE@]<VU(H;68QAY$]V;Q@Q1^*
M,AI9"OUF'[/T?$0)7%2*%K^S^KX6H4@>HO8%RI!8OLIWKCV,*\?!-`?-C?SB
M3Y5=4DC6)8:3Y>%19+0QRW"#;#?\N9+*XB-5$(C0U[O8AR;L2Q[:3ZZ<^DV6
M-RI`X4Z7'RYTH!+*Q6C*E*<^MW3Z]TF&1HI1P-D1V/?X2D:CP^<-M;<_.2=C
M6@A9'P%RR=2VTRP@S13AWUQ7E'77L*J8DNF/A[I`ABDN^PXLP08KF>-0D(J/
M5@9D?V"\I06):$?!3+(K(`X,1BL+FHH8#292PX,8!8FOI-3]=P1M<U720,8-
M[5545.QP9#O8?R7>LD47A-G!9+9E>*M"2-G\9;.ML\B2EC6Y#2\!C0JX;(Q6
M22"\TA&#7]Q$551@0N$[?O)+G[QOY#7VD\ZUM3U5OA=39U5C4;#?"A-I<L>M
<C,%-N\"I:R+!)41"2".^V(36)VE:LB2$70?_V3\_
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
